Ailani Myers Accelerating Innovation in Medicine to Cure Kids with Cancer Act
- Sponsor
- Rep. McCaul, Michael T. [R-TX-10]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Sep 14, 2026
Bottom line
This bill aims to accelerate pediatric cancer research and care by improving federal coordination, expanding data infrastructure, and leveraging artificial intelligence, with specific funding authorized for these efforts.
What it actually does
This bill establishes a Coordinator of AI Innovation to streamline federal efforts across multiple agencies in applying advanced technologies, including artificial intelligence, to pediatric cancer. It also mandates the National Cancer Institute (NCI) to expand its Childhood Cancer Data Initiative (CCDI) to better collect, standardize, and share pediatric cancer data, specifically enhancing its AI readiness and supporting AI-driven research and clinical trials. Furthermore, it directs the Department of Health and Human Services (HHS) to develop interoperability standards for patient data, prioritizing pediatric cancer needs, to facilitate AI integration into health information technology.
Proponents argue
Proponents argue that pediatric cancer research has historically lagged behind adult cancer research, and this bill provides a crucial, coordinated federal strategy to harness cutting-edge technologies like AI and robust data sharing to accelerate breakthroughs in diagnosis, treatment, and prevention for children. They emphasize the potential for AI to unlock new insights from complex data, leading to more personalized and effective therapies, ultimately saving young lives and improving long-term outcomes for survivors.
Opponents contend
Potential opponents might raise concerns about the significant financial investment required, especially given other pressing healthcare priorities, or question the immediate efficacy of AI in delivering tangible results for pediatric cancer within the proposed timeframe. Some might also express apprehension regarding data privacy and security implications when consolidating and sharing sensitive patient data, even with safeguards, or argue that existing initiatives could be better optimized without creating new coordination roles or mandates.
The bill is relatively short and clearly structured, allowing an informed reader to understand its core provisions and implications within a reasonable timeframe.
Title I, Section 101
Establishment of Coordinator of AI Innovation
This section requires the President to designate a federal officer, employee, office, council, or commission as the 'Coordinator of AI Innovation.' This Coordinator will be responsible for aligning and facilitating efforts across various federal departments and agencies (including HHS, DoD, DoE, NSF, NIST, OSTP) to use advanced technologies, especially AI, for improving pediatric cancer diagnosis, treatment, prevention, and cures. The Coordinator will also facilitate interagency and non-federal collaboration and align data and AI policies.
Supporters argue
Supporters argue that a dedicated coordinator is essential to overcome bureaucratic silos and ensure a unified, efficient federal approach to leveraging AI for pediatric cancer, maximizing the impact of research and development.
Critics contend
Some might argue that adding another layer of coordination could introduce more bureaucracy without guaranteeing tangible improvements, or that existing interagency mechanisms are sufficient if properly utilized.
Tradeoffs
The tension lies between the desire for centralized, efficient coordination and the potential for creating additional administrative overhead or diluting the autonomy of individual agencies.
Title II, Section 201
Mandating and Expanding the Childhood Cancer Data Initiative
This section mandates the NCI Director to carry out the CCDI to collect, generate, standardize, link, and share data on individuals diagnosed with cancer as children, adolescents, or young adults. It specifies components like molecular characterization, generation of data from non-invasive AI tools, data platforms (CCDI Data Ecosystem), collection of rare pediatric cancer data, aggregation of clinical/research/population data (National Childhood Cancer Registry), and development of data standards. It also establishes a CCDI Director.
Title II, Section 202
AI Development and Application in Pediatric Cancer
This section directs the NCI Director, in coordination with the Coordinator, to support the development and application of AI for pediatric cancer research and care, specifically through the CCDI. It mandates expanding AI readiness of CCDI data platforms, consolidating and harmonizing data for AI analysis, and developing AI-compatible data standards. It also supports AI research for predictive modeling, biomarker discovery, and clinical trial improvement.
Title II, Section 203
Enhancing Health Data Interoperability and Patient Engagement
This section directs the Secretary of HHS, through the National Coordinator for Health Information Technology, to integrate AI into interoperability activities to improve the use of electronic health record (EHR) and claims data for research and clinical trial design, while ensuring patient privacy. It mandates finalizing interoperability standards for patient data with AI within two years, specifically accounting for structured/unstructured data, safe exchanges, and prioritizing pediatric patient needs. It also requires consultation with stakeholders and identifying/addressing barriers to pediatric data sharing.
Title III, Section 303
Funding Authorization for Act Activities
This section authorizes appropriations for the activities outlined in the Act. Specifically, it authorizes 'such sums as may be necessary' for fiscal years 2027 through 2031 for all activities except Section 201 (CCDI). For Section 201 (CCDI), it authorizes $100,000,000 for each of fiscal years 2027 through 2031, in addition to the 'such sums as may be necessary' for other parts of the Act.
Defines 'artificial intelligence' by referencing section 238(g) of the John S. McCain National Defense Authorization Act for Fiscal Year 2019 (Public Law 115-232).
Title III, Section 301(2)
Why it matters:Standard legislative practice to maintain consistency in definitions across federal law, rather than re-stating complex definitions.
Case for: Provides legal consistency and avoids ambiguity by relying on an established definition, which is efficient for legislative drafting.
Case against: Requires extra effort for a lay reader or even a specialist unfamiliar with the referenced defense act to fully grasp the technical scope of the bill's core technology.
Estimated impact: Ensures that the AI efforts funded and coordinated by this bill adhere to a specific, pre-defined understanding of AI, potentially influencing the types of technologies and research that qualify.
Mandates that all activities under the Act, particularly data interoperability and sharing, must be carried out consistent with applicable Federal and State privacy laws, specifically referencing regulations promulgated under section 264(c) of the Health Insurance Portability and Accountability Act of 1996 (42 U.S.C. 1320d-2 note), commonly known as HIPAA.
Title II, Section 203(a) and Title III, Section 302
Why it matters:Standard legislative practice to leverage existing comprehensive regulatory frameworks rather than reinventing privacy rules for each new act. This ensures consistency with established privacy law.
Case for: Ensures that robust and well-understood privacy protections are automatically applied without needing to draft new, potentially conflicting, language. It provides a strong legal foundation for data security.
Case against: For a reader concerned about data privacy, simply referencing HIPAA might not be sufficient to convey the specific safeguards or potential vulnerabilities, requiring them to have a deep understanding of HIPAA regulations.
Estimated impact: Crucial for protecting sensitive patient data collected and shared under the Act, potentially influencing public trust and participation in data initiatives.